Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 1, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of insider trading activity and does not contain financial performance data.
Material Changes
The material change reported is the exercise of stock options and subsequent sale of shares by Mr. D. Phelan, a Person Discharging Managerial Responsibility:
- Option Exercise: On July 31, 2006, Mr. Phelan exercised options over 23,517 ADSs granted on November 21, 1996, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of $28.159 per ADS.
- Share Sale: On July 31, 2006, Mr. Phelan sold 23,517 ADSs at an average price of $55.31 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific transaction noted above in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of ADSs held by Mr. D. Phelan following the July 31, 2006 transactions.
- Confirm the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 referenced in the filing.
- Check for any other concurrent insider transactions not detailed in this specific Form 6-K.